<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02574390</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00082277</org_study_id>
    <nct_id>NCT02574390</nct_id>
  </id_info>
  <brief_title>Answer ALS: Individualized Initiative for ALS Discovery</brief_title>
  <acronym>AnswerALS</acronym>
  <official_title>Answer ALS -Creation of a Large Bio-repository of iPS Cells, Cell Lines, and Bio-fluid Samples, Combined With Clinical Information to Rapidly Advance Therapeutics That Could Treat ALS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ohio State University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Washington University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cedars-Sinai Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts Institute of Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York Genome Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Leandro P. Rizzuto Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Texas Neurology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Northwestern University Les Turner ALS Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Creation of a large repository of induced pluripotent stem cells (iPSC), bio-fluid samples
      (blood and spinal fluid (optional)), and cell lines for ALS gene identification. This will be
      combined carefully with collected measures of the pattern of the symptoms people with ALS
      have and how these change over time. People with other motor neuron diseases and healthy
      controls will be included as comparisons
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will have 5 study visits; screening, 3, 6, 9 and 12 months. There will be a one year
      post-participation follow-up period, during which they will receive an email or phone call
      interview once every 3 months. During the first year, samples will be collected, breathing,
      muscle strength, spasticity, general function and cognitive behavior will be assessed.
      Healthy controls will have 2 study visits during which blood samples will be collected and
      questionnaires given.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2019</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>1 Year</target_duration>
  <primary_outcome>
    <measure>ALS Functional Rating Scale-Revised (ALSFRS-R)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>12 questions about patient's ability to function in certain activities of daily living. Each question is out of 4 with 4 being normal and 0 being completely impaired.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ALS Cognitive Behavioral Scale (ALS-CBS)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>short measure of cognition and behavior in patients with ALS. The cognitive portion consists of 8 tasks with a perfect score being 20. The behavioral portion measures changes in personality and behavior since the onset of ALS symptoms as well as mood, pseudobulbar affect and fatigue and is completed by a family member or caregiver. A normal score is 45.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Slow Vital Capacity (SVC)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>measurement of the maximum amount of air that can be exhaled following a deep breath.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Strength Testing with Hand Held Dynamometer (HHD)</measure>
    <time_frame>once every 3 months for one year</time_frame>
    <description>muscle strength testing performed on upper and lower limbs, ankles, wrists and fingers using a small hand held device. These measurements are followed over time and compared to measure decline.</description>
  </primary_outcome>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Amyotrophic Lateral Sclerosis</condition>
  <condition>Primary Lateral Sclerosis</condition>
  <condition>Flail Arm ALS</condition>
  <condition>Progressive Muscular Atrophy</condition>
  <condition>Monomelic Amyotrophy</condition>
  <condition>Motor Neuron Disease</condition>
  <condition>Asymptomatic ALS Gene Carriers</condition>
  <condition>Healthy Controls</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      plasma, serum, DNA, Cerebrospinal fluid, induced pluripotent stem cells,
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients with ALS, Primary Lateral Sclerosis Flail Arm ALS Progressive Muscular Atrophy
        Monomelic Amyotrophy Motor Neuron Disease Asymptomatic ALS Gene Carriers
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with familial or sporadic ALS diagnosed as possible, laboratory-supported
             probable, probable or definite according to the World Federation of Neurology (WFN) El
             Escorial criteria, Primary Lateral Sclerosis Flail Arm ALS, Progressive Muscular
             Atrophy, Monomelic Amyotrophy, Motor Neuron Disease, Asymptomatic ALS Gene Carriers

          -  Participants who are ages 18-100, inclusive.

        Exclusion Criteria:

          -  Participants with Spinal-Bulbar Muscular Atrophy

          -  Known diagnosis of HIV/AIDS, Hepatitis B, or Hepatitis C.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas J Maragakis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James D Berry, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts Generel Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Betsy Mosmiller, BA</last_name>
    <phone>410-502-0495</phone>
    <email>emosmil1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peggy Allred</last_name>
      <phone>424-315-2694</phone>
      <email>Peggy.Allred@cshs.org</email>
    </contact>
    <contact_backup>
      <last_name>Dana Fine</last_name>
      <phone>310-423-8497</phone>
      <email>dana.fine@cshs.org</email>
    </contact_backup>
    <investigator>
      <last_name>Robert H. Baloh, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arish Jamil</last_name>
      <phone>404-727-1273</phone>
      <email>arish.jamil@emory.edu</email>
    </contact>
    <contact_backup>
      <last_name>Meraida Polack, RN</last_name>
      <phone>404-779-3807</phone>
      <email>mpolack@emory.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Glass, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Benjamin Joslin</last_name>
      <phone>312-503-7504</phone>
      <email>ben.joslin@northwestern.edu</email>
    </contact>
    <contact_backup>
      <last_name>Patricia Casey</last_name>
      <phone>312-503-7504</phone>
      <email>patricia-casey@northwestern.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Betsy Mosmiller</last_name>
      <phone>410-502-0495</phone>
      <email>emosmil1@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brixhilda Dedi</last_name>
      <phone>617-726-4284</phone>
      <email>bdedi@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jacqueline Andrews</last_name>
      <phone>617-726-0981</phone>
      <email>jandrews9@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>James D Berry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jesse Markway</last_name>
      <phone>314-747-7881</phone>
      <email>neuroclinicalstudies@neuro.wustl.edu</email>
    </contact>
    <contact_backup>
      <last_name>Jennifer Jockel-Balsarotti</last_name>
      <phone>314-362-6159</phone>
      <email>neuroclinicalstudies@neuro.wustl.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Timothy Miller, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43221</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ifeanyi Okoh</last_name>
      <phone>614-688-7837</phone>
      <email>ifeanyi.okoh@osumc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Sharon Chelnick, MHSA, CCRC</last_name>
      <phone>614-293-4973</phone>
      <email>sharon.chelnick@osumc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Stephen J Kolb, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Neurology</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Todd Morgan</last_name>
      <phone>214-827-3610</phone>
      <phone_ext>228</phone_ext>
      <email>tmorgan@texasneurology.com</email>
    </contact>
    <investigator>
      <last_name>Daragh Heitzman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 9, 2015</study_first_submitted>
  <study_first_submitted_qc>October 9, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2015</study_first_posted>
  <last_update_submitted>May 9, 2018</last_update_submitted>
  <last_update_submitted_qc>May 9, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 15, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALS</keyword>
  <keyword>stem cell</keyword>
  <keyword>biomarker</keyword>
  <keyword>disease progression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Atrophy</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
    <mesh_term>Muscular Atrophy</mesh_term>
    <mesh_term>Muscular Atrophy, Spinal</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

